Our Archives section provides access to previously published issues, ensuring a comprehensive resource for researchers, practitioners, and educators.
Explore Past Issues
Volume 1
Issue 2 JULY– DECEMBER 2025
Volume 1 (Issue 2) JULY– DECEMBER 2025 Research Articles
Nanocarrier-based delivery system Development and In-Vitro Evaluation of Paclitaxel in Triple-Negative Breast Cancer
Vol.1(2); Pages:1-12. Published on July-2025
Abstract
Triple-negative breast cancer (TNBC) is a virulent type of breast cancer that has few treatment choices because it does not have definite molecular targets. This paper discusses the formulation and in-vitro analysis of paclitaxel loaded nanocarrier system to enhance solubility, tumor specificity, and cytotoxicity of paclitaxel in TNBC. A modified solvent evaporation method was used to make nanoparticles, which were then characterized in terms of size, polydispersity index (PDI), zeta potential, and drug loading. Optimized formulation was found to have improved cellular uptake and two-fold cytotoxicity than free paclitaxel as tested in MDA-MB-231 cell line by MTT assay. These results indicate the delivery systems based on nanocarriers could considerably increase the therapeutic effect of paclitaxel, and this strategy represents a viable chance to improve outcomes of treatment in TNBC. These findings point to the promise of nanoparticle-based systems in addressing the issues inherent in the poor solubility and non-specific delivery of paclitaxel and forms the basis of future pre-clinical and clinical studies.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Triggered Dose System Nanoparticle Cisplatin Treatment of Refractory Ovarian Cancer: a Phase II Randomized Trial
Vol.1(2); Pages:13-23. Published on July-2025
Abstract
In this randomized controlling protocol, the encapsulation is assessed in terms of the safety and efficacy of cisplatin embedded in biodegradable lipid-based nanoparticles in patients with refractory ovarian cancer that has not responded to conventional platinum-based regimens. The 120 patients were randomly assigned and administered usual cisplatin by infusion or nanoparticle wrapped cisplatin. Progression-free survival (PFS) was the main endpoints, and the secondary endpoints were toxicity profile and quality of life. Encapsulated, nanosized cisplatin led to a 35% PFS increment, diminished nephrotoxicity, and ototoxicity, and increased toleration to therapy. In vitro analyses showed an increase in uptake into tumor and a reduction in drug exposure to other body systems. The results of this study lend credence to the clinical prospect of nanoparticlemediated cisplatin delivery in case of refractory gynecological malignancies and warrants further Phase III trials.
View Full PDF
Please LOGIN to View Full PDF or Read more.
A Multicentric Observation Pharmacogenomic Determinants of Tamoxifen Resistance in Postmenopausal Breast Cancer
Vol.1(2); Pages:24-34. Published on July-2025
Abstract
One of the challenges of postmenopausal breast cancer is the Tamoxifen resistance. A total of 450patients enrolled in this multicenter observational study in six European oncology centers were used to determine genetic polymorphisms associated with adverse therapeutic outcomes. Peripheral blood genotypes were tested to identify variants in genes CYP2D6, ESR1 and SULT1A1 influencing the metabolism and binding to receptor of tamoxifen. CYP2D6 Determinants Poor metabolizer genotypes of CYP2D6 were linked with a twofold increase in relapse risk in the three year interval as requested extensive metabolizers. The polymorphisms of ESR1 were associated with reduced sensitivity to estrogen receptor and they have been proved to be in resistance. Applying precision pharmacogenomics screening to breast cancer treatment with an emphasis on studying tamoxifen therapy, the study proposes that adding blood-based pharmacogenomic screening performed prior to tamoxifen therapy exposes patients to alternative therapeutic pathways to tamoxifen use, including aromatase inhibitors.
View Full PDF
Please LOGIN to View Full PDF or Read more.
A Phase II Trial of Efficacy of a Combination of Immune Checkpoint Inhibitors and Low-Doses of Chemotherapy in Metastatic Melanoma
Vol.1(2); Pages:35-43. Published on August-2025
Abstract
The trial was a Phase II clinical trial that assessed the efficacy of the use of low-dose dacarbazine chemotherapy combined with PD-1 inhibitor in individuals with a metastatic melanoma who were 92. The patients were randomly allocated in both the immune checkpoint inhibitor (ICI) monotherapy and combination regimen. Overall response rate (ORR) and progression-free survival (PFS) were the major endpoints. The combination arm had an ORR of 48 percent, 29 percent in the monotherapy arm, and mean PFS benefits of 4.2 months. Combination group tended to have more CD8+ T-cell infiltrate and produce more IFN-y following -immune profiling. Notably, the inclusion of chemotherapy did not make any significant difference in grade 3 or higher toxicities implying the safety profile. These results substantiate the combination regimen in the therapeutic management of melanoma and provide the basis of extended trials.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Meta-Analysis and Systematic Review of the Oral PARP Inhibitors in Advanced Prostate Cancer
Vol.1(2); Pages:44-52. Published on August-2025
Abstract
Poly (ADP-ribose) polymerase (PARP) inhibitors have been highly promising agents in targeted therapy against advanced prostate cancer and particularly patients with BRCA1/2 and other homologous recombination repair (HRR) gene mutations. The study is a systematic review and meta analysis of 14 randomized control trials, which include 2865 patients that received treatment with PARP inhibitors (olaparib, rucaparib and niraparib). Key endoints overall survival (OS), radiographic progression-free survival (rPFS), and incidence of adverse events indicated a significant 5.8-month overall survival gain with PARP inhibitors, with the largest benefit in BRCA-mutated subgroups. Also, rPFS was also extended persistently. Most frequent toxicities were hematologic: most often the anemia or thrombocytopenia. The results confirm the importance of PARP inhibitors as a potentially useful anti-cancer drug against advanced prostate cancer and indicate that genomic analysis is required to select potential patients to whom the therapy can be administered.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Issue 1 JANUARY- JUNE 2025
Volume 1(Issue 1) JANUARY- JUNE 2025 Research Articles
Harnessing Digital Innovation in Pharmacies: Advancing Daily Healthcare through Pharmacy 4.0 Technologies
Vol.1(1); Pages:1-9. Published on June-2025
Abstract
Changing healthcare needs, new policies and efforts to provide patients with cheaper and more accessible care are bringing about a revolution in community pharmacy practice in the United States. As a result of this change, community-based pharmacists now provide comprehensive clinical services, manage ongoing diseases, prevent illnesses, supervise medication therapy, give vaccinations and extend public health outreach. Thanks to new service models such as appointments for medication order synchronization, team agreements and including digital solutions, pharmacists play an active role in supporting all members of a healthcare team. They are especially useful in under-served regions, since CBPPs work to address important shortages in primary care. Covid-19 emphasized the important role of pharmacists, who saw both advantages in regulations and a broader area of work. Even so, there are hurdles to overcome in getting reimbursed, being recognized as healthcare providers and creating standard training across countries. It brings together fresh improvements, current policies and research on the expanding clinical, financial and public health roles of community pharmacists in the U.S. and recommends building a sustainable system to ensure their full inclusion in healthcare.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Key Advances in Pharmacological Approaches to Clinical Nutrition Therapy: 2016 Evidence Update
Vol.1(1); Pages:10-17. Published on June-2025
Abstract
In 2016, pharmacy experts began collaborating more with those in nutrition to ensure better results for patients in healthcare settings. During that period, leading studies examined the pharmacology of parenteral and enteral nutrition, how nutrients and drugs affect each other and the role of pharmacists in nutritional care. At this time, there were major advances in using research-based care approaches, mainly in critical care, oncology and after surgery. New studies revealed that when nutrients are given according to each person’s needs by clinical pharmacists, it helps avoid refeeding syndrome, plan vitamin and mineral usage and keep IV mixtures safe for use. Furthermore, the American Society for Parenteral and Enteral Nutrition (ASPEN) helped polish existing guidelines which also supports pharmacists working alongside other members of nutrition teams. Literature in this field emphasized why ongoing learning, making new protocols and increasing the involvement of pharmacists are necessary to boost the standards in nutrition support care.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Assessment of Patient Satisfaction with Pharmacy Services in Tertiary Hospitals
Vol.1(1); Pages:18-25. Published on June-2025
Abstract
The way patients feel about their care is very important in healthcare quality and this applies strongly to pharmacy services, as they ensure medications are used properly. We conducted this review to study how satisfied customers are with pharmacy services in tertiary care hospitals. It studies important aspects of satisfaction such as facility access, how pharmacists communicate with patients, waiting periods, the existence of needed medications and the standard of the provided service. The review brings together different studies to highlight similar successes and highlight which areas should be improved in hospital pharmacy operations. Researchers emphasize that patients are more satisfied and achieve better results from treatment when there is ongoing feedback and pharmacists are involved. The findings can shape both new policies and improvements in tertiary care settings.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Effects of COVID-19 Lockdowns on Pharmacy Education via Virtual Gamified Simulations
Vol.1(1); Pages:26-33. Published on June-2025
Abstract
The COVID-19 pandemic caused big changes in how healthcare education was delivered, leading to the fast adoption of online classes. Virtualized gamified pharmacy simulations became a key way to help pharmacy students maintain their learning despite outside factors. This research examines how virtual gamified simulations were introduced in pharmacy education, what the effects were and what students thought. By organizing virtual games in place of the lab and classroom, institutions allowed students to experience the same important clinical situations and make key decisions when learning from a distance. Researchers bring together evidence from leading institutions worldwide to explore the effects on students’ memory, real-life learning, satisfaction and successful learning. In addition, the research examines what learning theories underlie gamification, the programs used and the obstacles faced when introducing it. Evidence reveals that virtual games for pharmacy education, introduced because of the pandemic, may also help create new hybrid methods for teaching and learning. The study ends by suggesting the inclusion of gamified digital tools in pharmacy programs to boost resilience, more engaging learning and student results everywhere.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Hospital Pharmacies’ Evaluation of UVC Sterilization Equipment: Analyzing Its Contribution to Infection Control
Vol.1(1); Pages:34-42. Published on June-2025
Abstract
This project studies how well and how easily Ultraviolet C (UVC) technologies can be used to clean up and sanitize hospital pharmacies. Since controlling infection is critical, especially in sensitive areas of pharmaceutical compounding and storage, UVC technology meets this need safely and efficiently. This research examines how well disinfection works, the plans for setting up devices, worker protection concerns and issues with system integration. Reduced microbial loads on surfaces and equipment in the results show that UVC can help improve hygiene in the pharmaceutical industry. Still, attention to how long the treatment is applied, the impact of shadowing and maintenance suggests that implementation must be exact.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Stay Updated
To stay informed about the latest research and updates in the journal, consider subscribing to our newsletter or following us on social media.
